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Cases of diarrhoeal disease number from 1.7 to 5 billion per 
year worldwide. One of the main causes of diarrhoeal disease 
is typhoid fever, which is a potentially life-threatening multi-sys-
temic illness. According to the most recent estimates, a total of 
26.9 million typhoid fever episodes occurred in 2010. The geo-
graphical distribution of the disease differs widely; in developed 
countries, the incidence rate per 100,000 per year varies from 
<  0.1 to 0.3, and the disease mainly affects people who travel 
to endemic areas located in low- and middle-income countries. 
Low- and middle-income countries are mainly affected owing 
to the lack of clean water and proper sanitation. In the fight 
against this plague, prevention is fundamental, and vaccination 
against typhoid is an effective measure. Vivotif® is an oral live 
attenuated vaccine which contains a mutated strain of Salmonella 
(Ty21a) and reproduces the natural infection. The vaccine was 
first licensed in Europe in 1983 and in the US in 1989, and over 
the years it has proved efficacious and safe. It is indicated for 
adults and children from 5 years of age upwards. Specifically, in 
the most developed countries, vaccination is suggested for high-
risk population groups and particularly for international travel-
lers to destinations where the risk of contracting typhoid fever 
is high. It must also be borne in mind that international travel 
is increasing. Indeed, international tourist arrivals totalled 1,184 
million in 2015 and, on the basis of current trends, international 
travel is expected to grow by 3-4% in 2017. Vivotif® appears to be 
a powerful means of disease prevention, the importance of which 
is highlighted by the spread of antibiotic-resistant strains of Sal-
monella typhy (S. typhi).
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Summary
Introduction
Typhoid Fever (TF), also known as enteric fever, is a 
potentially life-threatening multi-systemic illness. It is 
mainly caused by Salmonella enterica, subspecies en-
terica serovar typhi, and to a lesser extent by serovars 
paratyphi A, B, and C, which are members of the family 
of Enterobacteriaceae [1]. The genus Salmonella is di-
vided into serotypes, on the basis of surface antigens: O 
antigen based on the lipopolysaccharide component, and 
H antigen based on flagellar proteins. Moreover, patho-
genic strains of S. typhi and S. paratyphi C present a Vi 
antigen polysaccharide component [2].
The burden of diarrhoeal disease is very high, account-
ing for 1.7 to 5 billion cases per year worldwide [3, 4]. 
The main risk factors of diarrhoeal disease are inade-
quate drinking water and inadequate sanitation; indeed, 
in 2014 the World Health Organization (WHO) attrib-
uted 502,000 deaths to inadequate drinking water and 
280,000 to inadequate sanitation [5, 6]. Furthermore, ac-
cording to WHO estimates, TF is one of the main causes 
of foodborne deaths and results in the greatest loss of 
Disability-Adjusted Life years (DALYs) worldwide [7]. 
Some authors have called TF “an old plague”, asserting 
that “currently, despite major efforts in preventing and 
treating cases of enteric fever, millions of new infections 
(approximately 21 million new cases per year) of ty-
phoid and paratyphoid fevers occur in many areas where 
poor sanitation and unsafe food and water access occurs 
frequently and among travellers to endemic areas” [8].
In the fight against this plague, preventive measures are 
fundamental. Vaccination against typhoid is an effective 
preventive intervention, especially when coupled with 
hand-washing, the treatment of household water, and the 
provision of adequate sanitation [9].
Currently, two well-tolerated and effective vaccines are 
available. One is based on the use of live attenuated bac-
teria and is administered orally; the other is based on 
Vi capsular polysaccharide (Vi-PS), and is administered 
intramuscularly or subcutaneously [9].
In the present overview, we investigated the epidemio-
logical impact of typhoid and paratyphoid fever and as-
sessed the utility of Ty21a vaccine (Vivotif®) and vac-
cination policies.
Epidemiology
As mentioned above, TF is one of the main causes of en-
teric disease worldwide [10]. The incidence of typhoid 
fever (overall population) is reported in Figure 1.
According to the most recent estimates, a total of 26.9 
million typhoid fever episodes occurred in 2010 [11-14]. 
The distribution of the disease differs widely through-
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out the world. In developed countries, the incidence rate 
per 100,000 per year varies from < 0.1 to 0.3, and the 
disease mainly affects people who travel to endemic ar-
eas located in low- and middle-income countries  [11]. 
Low- and middle-income countries are mainly affected 
owing to the lack of clean water and of proper sanitation; 
indeed, the known risk factors for TF are: high popula-
tion density, unsanitary living conditions, poor hygiene, 
low socio-economic status, and recent contact with a pa-
tient affected by TF [15]. TF has a heavy burden in Asia, 
with an overall incidence of 170.8 cases per 100,000 
people per year, though this estimate varies across the 
continent  [11]. Specifically, Buckle et al. estimated an 
annual incidence rate of 394.2 per 100,000 in southern 
Asia. With regard to Africa, the incidence is estimated to 
be 724.6 cases per 100,000 people per year; however, it 
is probably underestimated, owing to the lack of infor-
mation and surveillance systems in the continent  [11]. 
Moreover, Africa suffers many cases of invasive non-
typhoid salmonellosis, which are additional confound-
ing factors in estimating the typhoid fever burden [15]. 
Typhoid fever also affects countries in Latin America, 
the Caribbean and Oceania, although to a lesser extent, 
with a median incidence rate of 22.3 cases per 100,000 
people per year [14].
The 5-15 year-old age-group is considered the main tar-
get of the disease. Notably, even when properly treated, 
children have a high case fatality rate.
The median FT mortality rate varies from region to re-
gion: high-income countries such as North America, Eu-
rope, Australia and New Zealand register less than 0.1 
death per 100,000 people per year, while the mortality 
rate is higher in Sub-Saharan Africa (7.2) and Southern 
Asia (3.9) [11].
S.  paratyphi causes paratyphoid fever. S.  paratyphi is 
thought to cause milder disease than S. typhi, with symp-
toms being predominantly gastrointestinal  [16]. While 
this is probably true of S. paratyphi B infection, there are 
insufficient data to draw conclusions regarding S. para-
typhi A [17]. In 2000, 5.4 million cases of paratyphoid 
fever were estimated to have occurred, with incidence 
rates ranging from 8 cases per 100,000 people per year 
in high-income countries to 77.4 in low-income coun-
tries. Specifically, in Eastern and Southern Asia, the an-
nual incidence is 17.9 cases per 100,000 people. More-
over, S. paratyphi A has been found to be responsible 
for a considerable, and increasing, proportion of cases of 
enteric fever in some Asian regions [13].
The impact of S. typhi and S. paratyphi disease is prob-
ably underestimated because of inadequate surveillance 
systems in the most severely affected areas, the low sen-
sitivity of diagnostic tools and healthcare inequalities 
resulting in low health-seeking behaviour among popu-
lations at the highest risk [8].
Typhoid fever disease
S. typhi is restricted to human hosts, and chronic carriers 
constitute the reservoir of infection.
Fig. 1. Typhoid fever incidence (from Mogasale, et al., mod. [63]).
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The disease is mainly transmitted through the consump-
tion of food, drink or water that have been contaminated 
by the faeces or urine of subjects excreting bacteria (sick 
or convalescent people or chronic asymptomatic car-
riers). After S.  typhi has been ingested, it reaches the 
intestinal epithelium, where it colonizes macrophag-
es and dendritic cells in the lamina propria; but these 
fail to destroy the bacterium  [9]. Subsequently, bacte-
ria invade the bloodstream, multiply and spread to the 
lymph nodes, spleen and liver, causing multi-systemic 
disease [14]. The main manifestations of the disease are 
fever, which can reach 38°-40°C, and abdominal symp-
toms (such as diarrhoea or constipation). Nonspecific 
symptoms, such as weakness, anorexia, headache and 
dizziness, may precede the fever. Moreover, rose-col-
oured spots may appear on the trunk, and patients may 
also experience neuropsychiatric manifestations, hepa-
tomegaly and splenomegaly. The most severe complica-
tions are gastrointestinal bleeding, intestinal perforation 
and typhoid encephalopathy, which occur in 10-15% of 
patients, generally in the third and fourth weeks of infec-
tion [18, 19]. The duration of infection is a major deter-
minant of the risk of severe complications, and a delay in 
administering appropriate antibiotic treatment may have 
serious consequences.
Isolation of S.  typhi from blood is the most common 
method of diagnosis, though the bacterium can also be 
isolated from bone marrow, faeces and duodenal fluid. 
Blood culture displays suboptimal sensitivity, generally 
being positive in only about 50% of cases. Blood cul-
ture also has several limitations, including the volume of 
blood needed, the need for prompt transport to the labo-
ratory, interference due to prior antibiotic use, limited 
laboratory expertise and equipment, and expense  [13]. 
Bone marrow culture increases the diagnostic yield to 
approximately 80% of cases. Stool culture is not usu-
ally positive during the earliest phase of the disease [20]. 
Multiple cultures increase sensitivity and may be re-
quired in order to reach a diagnosis.
Although the Widal test is unreliable, it is widely used 
in developing countries because of its low cost. Newer 
serologic assays for S.  typhi infection are occasionally 
used in outbreak situations, and are somewhat more sen-
sitive and specific than the Widal test; however, they are 
not an adequate substitute for blood, stool, or bone mar-
row culture [1].
Early diagnosis and the prompt institution of appropriate 
antibiotic treatment are essential for the optimal man-
agement of TF, especially in children. Ciprofloxacin is 
commonly used as an empiric treatment, as fluoroquino-
lones are recommended. However, as fluoroquinolone-
resistant or multidrug-resistant strains are spreading, 
third-generation cephalosporins are used when the pos-
sibility of resistance is high [18, 19].
Preventive measures
In the late 19th and early 20th centuries, typhoid was 
endemic in all countries, including Europe and the 
Americas. Subsequently, the widespread use of chlori-
nation, sand filtration, and other means of water treat-
ment drastically reduced the incidence of TF, despite the 
high prevalence of chronic carriers [14]. Today, TF still 
places a devastating burden on many low- and middle-
income countries; in high-income countries, the impact 
of the disease is mainly linked to travel to endemic dis-
ease areas [16].
Prevention by vaccines
Currently, 2 typhoid vaccines are internationally avail-
able, and both have been shown to be safe and effica-
cious [9].
The first is an oral vaccine based on a live attenuated 
S. typhi Ty21a strain (Vivotif®), which has been devel-
oped in two formulations: enteric coated capsules and a 
liquid formulation. On the market Vivotif® is available in 
enteric coated capsules.
The second is a Vi capsular polysaccharide (Vi-PS) 
vaccine, which is injectable. Furthermore, typhoid con-
jugate vaccines (TCVs) have been developed, one of 
which is based on Vi conjugated to rEPA, a recombinant 
exoprotein A from Pseudomonas aeruginosa [22]. Two 
Vi-tetanus toxoid conjugate vaccines have recently been 
licensed in India [22].
Ty21a vaccine (Vivotif®)
Vivotif® is a vaccine which contains a mutated strain of 
Salmonella (Ty21a) and reproduces the natural infec-
tion. The Ty21a strain is a mutant of Ty2 strains lacking 
Uridine-diphosphate-galactose (UDP-Gal)-4-epimerase. 
It was obtained in the early 1970s by chemically inacti-
vating the galE gene. Inactivation of the galE gene gen-
erates a complete lack of Uridine-diphosphate-galactose 
(UDP-Gal)-4-epimerase, which is responsible for the 
conversion of UDP glucose into UDP galactose. As ga-
lactose is incorporated into lipopolysaccharide (LPS) as 
UDP galactose, the lack of galE produces incomplete 
development of LPS; this results in LPS without the O 
antigen, which is the chief surface antigen; in this phase, 
the mutant strain is not immunogenic. However, when 
the Ty21a strain is alimented by galactose, bacteria are 
able to generate UDP galactose in an alternative way, ex-
pressing a complete and immunogenic LPS. Moreover, 
owing to the lack of UDP Gal 4-Epimerase, galactose 
cannot be metabolised and is accumulated in the cyto-
plasm, resulting in lysis of bacteria and thus eliminating 
the virulence of the vaccine strain [23-26].
The vaccine was first licensed in Europe in 1983 and in 
the US in 1989.
The vaccine is administered orally through the ingestion 
of gastro-resistant capsules (one capsule on days 1, 3 
and 5) [27]. It is indicated for adults and children from 
5 years of age upwards.
The availability of an oral vaccine constitutes a major 
step forward in the prevention of typhoid fever, as oral 
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administration efficaciously stimulates the mechanisms 
of local, cell-mediated and systemic antibody immunity. 
Parenteral vaccines lack this triple action.
In countries where the risk of contracting the disease is 
high, vaccination is recommended every 3 years.
Revaccination every year is recommended if the subject 
travels from a non-endemic area to an endemic area.
The vaccine can be administered simultaneously with 
other vaccines and with antimalarial prophylaxis [28].
Vivotif® can be given to HIV-positive subjects who have 
a CD4 count above 200/mm3.
Immunogenicity
The immunogenicity of Ty21a vaccine has been evalu-
ated in children and adults in several studies. The as-
sessment of immunogenicity is an important proxy in 
evaluating efficacy/effectiveness with regard to both the 
specific strain and paratyphoid fever pathogens.
The vaccine has proved to elicit a good local production 
of IgA against the O antigen and to induce good humoral 
and cell-mediated immunogenicity against the O antigen 
in adult male subjects [29]. 
The immunogenicity of the Ty21a vaccine was evaluated 
in 634 Thai children who underwent a three-dose im-
munization schedule [30]. A seroconversion rate of 60% 
in 3-year-old and 91% in 6-year-old vaccinated children 
(p  <  0.005) was found; this was higher than the sero-
conversion rate in unvaccinated age-matched children. 
Seroconversion rates displayed an increasing trend with 
age in vaccinated children.
Gilman et al.  [31] showed that 155 adult males vacci-
nated with Ty21a vaccine had very good rates of sero-
conversion of antibodies against the O antigen, resulting 
in protection from disease.
A study carried out in young Chilean adults (15-19 years 
old) revealed that serum Ig O antibodies, as assessed by 
means of ELISA, increased when several doses of the 
vaccine were administered within a week  [32]. In an-
other study, the Ty21a vaccine elicited a strong systemic 
CD4+ T-helper type 1 response; booster doses induced a 
significant increase in levels of IgG and IgA anti-LPS in 
healthy adults [33].
Recently, a study involving volunteers was performed in 
order to evaluate the immune response against S. typhi, 
paratyphyi A, B and C (cross-reactive). Evaluating spe-
cific plasmablasts expressing homing receptors for in-
testine (α4β7) demonstrated that the response was great 
for S. typhi, intermediate for S. paratyphi B and low for 
S. paratyphi A [34]. In a recent study, Wahid et al. in-
vestigated the Ty21a-elicited antibodies which mediate 
the opsonophagocytosis and intracellular killing of S. ty-
phi, S. parathypi A and B. The authors found that, after 
immunization with Ty21a vaccine, opsonophagocytosis 
increased against S. typhi and, in to a lesser degree, also 
against S. paratyphi A and B [35].
Efficacy and effectiveness
The basic evidence that the Ty21a vaccine protects na-
ïve subjects stems from an experimental study in which 
adult subjects were challenged with wild S.  typhi 5-9 
weeks after vaccination. Subjects who had received the 
attenuated strain had a lower attack rate than control 
subjects (87% efficacy, p = 0.0002) [36].
In pre-licensure studies, 4  formulations of the vaccine 
were evaluated, namely: a lyophilized/bicarbonate for-
mulation “Alexandria formulation”, a gelatine capsule/
bicarbonate formulation, an enteric-coated capsule 
formulation, and a sachet “liquid” formulation. Three 
doses (48 hours apart) of the first formulation were ad-
ministered to 16,486 Egyptian children (aged 6-7 years) 
while 3 doses of placebo were administered to 14,557 
control group children. Subjects were followed up for 
three years, during which time 22 cases of typhoid fever 
were bacteriologically confirmed in the placebo group 
and one only case was confirmed in vaccine recipients 
(efficacy 95.6%; CI: 77-99%, p = 0,001]) [37]. The gela-
tine capsule/bicarbonate formulation proved to confer 
poor protection, and its development was soon aban-
doned [38].
In a clinical trial performed in Chile on the enteric-
coated capsule formulation, a total of 43,759 schoolchil-
dren (aged 6-17 years) received three doses of vaccine. 
Volunteers were randomly assigned to two groups, one 
of which received the three capsules within 48 hours 
(22,179 subjects), and the other within 21 days (21,598). 
In addition, children (21,906) who received placebo 
served as the comparator group. Over the 3-year follow-
up period, 68 cases of typhoid fever were bacteriologi-
cally confirmed in the placebo group, 23 cases were 
observed in subjects on the short-interval regimen (ef-
ficacy 67%; CI: 47-79%, p < 0.0001), and 34 cases were 
confirmed in the long-interval group (efficacy 49%; CI: 
24-66%, p = 0.0006) [38].
Although the clinical trials of the enteric-coated capsule 
formulation allowed the Ty21a vaccine to be authorized 
in several countries, another formulation was tested with 
the aim of achieving greater efficacy. This formulation, 
named “sachet liquid formulation”, consisted of a vac-
cine sachet containing lyophilized Ty21a bacteria and 
another sachet containing a buffer. To formulate the 
liquid suspension, the contents of the two sachets were 
mixed in 100 ml of water. In order to study the efficacy 
of this formulation, two large clinical trials were organ-
ized  [39, 40]. The first was implemented in Chile and 
the second in Indonesia. In Santiago, 36,623 schoolchil-
dren were recruited for the administration of three dos-
es of the vaccine, while a comparable group of 10,302 
children constituted the placebo control group. Over a 
3-year period of follow-up, a significant difference was 
observed in the incidence of bacteriologically confirmed 
typhoid fever, which yielded a vaccine efficacy rate of 
77% (CI: 60-87%, p < 0.0001).
The two above-mentioned formulations of the Ty21a 
vaccine (enteric-coated capsule and sachet liquid for-
mulation) were compared in a large randomized dou-
ble-blind trial in Indonesia, in which 20,543 subjects 
(aged 3-44 years) received 3 doses of either placebo or 
Ty21a vaccine in enteric-coated capsules or in liquid 
formulation. All subjects were observed for a follow-up 
period of 30 months; the rates of blood-culture-positive 
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typhoid fever recorded were: 810 per 100,000 per year 
among controls, 379 in the liquid-formulation group, 
and 468 in the coated-capsule group. Vaccine efficacy 
was assessed as 53% for the liquid formulation and 42% 
for capsules [40].
In 2007, Fraser et al. carried out a systematic review 
and meta-analysis of randomised controlled trials on Ty-
phoid vaccines. Concerning the Ty21a vaccine (3-dose 
regimen), efficacy was 49% (95% CI: 16-70%), 60% 
(95% CI: 44-71%), 59% (95% CI: 32-75%), 78% (95% 
CI: 35-93%) and 47% (95% CI: 24-78%) after 1, 2, 3, 4, 
and 5 years of follow-up, respectively [41].
With regard to effectiveness, an enlarged study was 
conducted in Chile on 222,998 subjects, the aims be-
ing to verify the possibility of introducing school-based 
mass vaccination and to ascertain the best management 
of the vaccination. This investigation demonstrated the 
good effectiveness of the vaccine and revealed that the 
regimen of three doses within seven days was the best 
schedule for the routine vaccination of the target popula-
tion [42].
The effectiveness studies carried out in Chile provided 
information on herd immunity effect of Ty21a vaccine; 
large-scale vaccination appeared to elicit a herd-immu-
nity effect. Two plausible explanations were formulated: 
first, the excretion of S. typhi significantly decreased in 
vaccinated subjects, causing less environmental contam-
ination; second, the smaller number of temporary car-
riers reduced S.  typhi transmission, thereby extending 
protection to unvaccinated subjects [24].
Safety and tolerability
The manifold mutations of the Ty21a vaccine make it 
genetically very stable; indeed, reversion to virulence 
has not been observed either in vitro or in vivo [31].
In a study conducted in children (6-7 years) in Alexan-
dria, Wahadan et al. demonstrated the very good safe-
ty and tolerability of the Ty21a vaccine  [36]. In their 
controlled trial, the authors recruited 32,388 children 
(16,486 received the vaccine, 15,902 received oral pla-
cebo, and 25,625 did not receive either) and observed 
that, out of 92,675 doses administered, there were 49 
cases of vomiting among vaccinees, versus 21 in the pla-
cebo group; 1 case of fever after the vaccine and 3 cases 
in the control group, and finally 14 cases of abdominal 
pain in the vaccinated group, versus 2 cases in the place-
bo group. Obviously, the conclusion was that the vaccine 
was stable and safe. Furthermore, in the pilot phase of 
this trial, the Ty21a strain was never detected in the stool 
for two weeks after vaccine administration [41].
Subsequently, other studies  [43-45] demonstrated the 
good safety of the Ty21a vaccine. Indeed, the study con-
ducted on adults in Chile recorded the following adverse 
reactions in 385 vaccinees: diarrhoea 1.8%, vomiting 
0.5%, fever 0.5%, and rash 0.5%, while in 367 placebo 
group subjects diarrhoea was found in 1.1%, vomiting 
in 0.3%, and fever in 0.6% of the subjects. In the study 
carried out in Indonesia on volunteers of all ages (311 
vaccinees with enteric-coated capsule vaccine versus 
291 placebo subjects): 3.9% of vaccinees versus 3.1% 
of placebo subjects had diarrhoea, 1.0% of vaccinees 
versus 1.7% of placebo subjects suffered from vomit-
ing, 1.7% of vaccinees versus 4.8% of placebo subjects 
had fever, and 0.3% of vaccinees versus 1.2% of placebo 
subjects had a rash.
Furthermore, in an extensive field study conducted 
with the Ty 21a vaccine on 555,000 schoolchildren in 
Chile  [46], passive surveillance did not find vaccine-
related adverse effects. Thus, it is now accepted that the 
Ty21a vaccine is very safe and very well tolerated, and 
that adverse reactions are rare and self-limiting and con-
sist of: abdominal discomfort, nausea, vomiting, fever, 
headache, and rash or urticaria [47, 48].
Indeed, in the period 1990-2000, more than 38 million 
persons received the Ty21a vaccine, with only 743 spon-
taneous reports of adverse effects, i.e. an incidence of 
0.002% [49]. The most common adverse reactions were 
mild, and mostly temporary, gastrointestinal disorders, 
followed by general reactions such as fever.
A post-marketing surveillance report published in 2001 
mentioned only minor and rare adverse reactions related 
with the Ty21a vaccine [47].
Cross-protection against paratyphoid fever
Studies aimed at evaluating the cross-protection of the 
Ty21a vaccine against paratyphoid fever have been car-
ried out. A study carried out in Area Norte and Occiden-
te of Santiago, Chile, demonstrated protection against 
paratyphoid B fever (efficacy 49%; 95% CI: 8-73%, 
p = 0.019) [50-54].
There is also some evidence of protection against S. para-
typhi A infections. Tagliabue et al. found that the Ty21a 
vaccine induced cellular immunity against S. paratyphi 
A and B, and supposed that the mechanism involved in 
cellular immunity would be that of antibody-dependent 
cellular cytotoxicity  [51]. A study by Pakkanen et al. 
demonstrated that the Ty21a vaccine was able to induce 
the presence of paratyphi A plasmablasts in the blood 
of vaccinees [34]. Furthermore, in 2012, Wahid R. et al. 
reported that subjects who had received the Ty21a vac-
cine displayed a humoral immune response of the same 
magnitude against both S. typhi and S. paratyphi A [35]. 
They demonstrated cross-reactive IgA of Antibody Se-
creting Cells (ASC) responses to S.  paratyphi A and 
S. paratyphi B LPS following Ty21a vaccination. A sub-
sequent investigation by the same researchers showed 
that, although the opsonophagocytic antibodies elicited 
by vaccination were not able to kill S. paratyphi A inside 
the macrophages, phagocytosis of S. paratyphi A bacte-
rial cells was increased owing to opsonisation, albeit to 
a lesser degree than that of B bacterial cells [53]. Sub-
sequently, Wahid R et al. investigated the activity of the 
Ty 21a vaccine in cross-reactive multifunctional CD8+ 
T cell responses against S.  typhi, S.  paratyphi A and 
S. paratyphi B in humans [54]. They demonstrated that 
the oral vaccine elicited specific cell-mediated immune 
responses against S. typhi and S. paratyphi B, and post-
vaccination increases in specific CD8+ T cell responses 
were observed against all three Salmonella-infected 
targets. This increase was seen predominantly in the T 
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Effector/Memory (TEM) cells and in the CD8+CD45RA+ 
TEM (TEMRA subsets) cells. In another study, these re-
searchers confirmed that live oral typhoid vaccine induced 
multifunctional S. typhi-specific CD4+ T cell responses that 
cross-react with S. paratyphi A and S. paratyphi B [54].
These results suggest that the oral live attenuated vaccine 
elicits protection against S. paratyphi A and S. paratyphi 
B. This, albeit modest, degree of protection could, how-
ever, yield a milder course of the disease, and may re-
duce contagiousness. This view is theoretically support-
ed by comparative whole-genome analysis, which shows
a high degree of homology among S. typhi, S. paratyphi
A and S. paratyphi B [55, 56].
Importance of vaccination in the light of 
S. typhi antibiotic resistance
As the antibiotic resistance of S. typhi continues to increase, 
the immunization of subjects at risk appears crucial to con-
taining the spread of typhoid fever. Indeed, since 2001, over 
the complete genome sequence of Multiple Drug Resist-
ant (MDR) S. typhi, the genes of resistance to antibiotics 
commonly used in the treatment of typhoid fever, and es-
pecially to fluoroquinolones, have been identified. Parkill 
et al. demonstrated that the genes of antibiotic resistance 
were located in pHCM1 and pHCM2 plasmids and were: 
the dhfr1b (trimethoprim), su/II (sulphonamide), catI (chol-
armphenicol), bla (TEM-1; ampicillin) and strAB (strep-
tomycin) genes [57]. More recently, a study conducted on 
African isolates suggests that there are at least 3 important 
MDR lineages (namely: A [haplotypes H56 and, rarely, 
H42], B [haplotype H55], and C [haplotype H77]  [58]. 
These can be added to the well-known H58 haplotype. The 
H58 haplotype acquired plasmid-encoding resistance to 
ampicillin, chloramphenicol and co-trimoxazole, and later 
acquired resistance to ciprofloxacin because of a chromo-
somal point mutation [59].
Infection caused by the MDR strains has been document-
ed to be associated with more severe illness and higher 
rates of complications and death, and with a higher rate 
of prolonged asymptomatic carrier status [60].
Conclusions
Enteric fever is a major public health challenge. As the 
spread of MDR strains of S. typhi is increasing, global 
strategies for combating S.  typhi infections need to be 
improved. In this perspective, the most effective way to 
fight typhoid fever and its severe complications is to im-
prove sanitation, ensure safe supplies of food and water, 
identify and treat chronic carriers, and implement vac-
cination. The typhoid vaccine appears to be a powerful 
means of prevention, and the WHO recommends that 
countries should consider the programmatic use of ty-
phoid vaccines in order to control endemic disease [60].
A study carried out by Watson et al. has shown that an 
efficient vaccination programme against typhoid fever 
can be cost-saving to health services in countries where 
the disease is endemic; moreover, targeting vaccination 
to the most seriously affected age-groups would improve 
cost-effectiveness [61].
The WHO recommends the vaccination of school-age and/
or preschool-age children in areas where typhoid fever in 
these age-groups is known to be a significant public health 
problem, particularly where antibiotic-resistant S.  typhi 
is prevalent, and during outbreaks  [60]. In the most de-
veloped countries, vaccination is suggested for high-risk 
population groups (such as persons with intimate exposure 
to chronic carriers, microbiologists and other laboratory 
workers), and particularly for international travellers to 
destinations where the risk of typhoid fever is high and/or 
in locations where antibiotic-resistant strains of S. typhi are 
prevalent. It must also be borne in mind that international 
travel is increasing. Indeed, in 2010, the number of interna-
tional tourist arrivals worldwide reached 949 million, and 
a total of 1,184 million was registered in 2015, according 
to the latest UNWTO World Tourism Barometer [62]. On 
the basis of current trends, international travel is expected 
to grow by 3-4% in 2017.
In conclusion, Vivotif® appears to be a powerful means 
of preventing enteric fever. Indeed, over the years it has 
proved efficacious, eliciting a triple immunologic re-
sponse. Furthermore, clinical studies have also demon-
strated its partial cross-protection against S. paratyphi and 
large-scale vaccination has appeared to elicit a herd-im-
munity effect. The vaccine is very safe and well tolerated, 
and its oral administration ensures very good compliance.
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